Emily Hickson in Commack, New York

Home New York Commack

Emily Hickson has Nurse Practitioner as her primary medical specialty. Their primary office is: 650 Commack Rd in Commack, New York. There is an additional office location, for a total of two, for Emily Hickson that can be viewed further down.

They're a part of the: Mskcc Regional Network medical group which has around 69 members. You can call their office at 631-623-4034 to schedule an appointment. They also accept the Medicare-approved amount as payment in full. They attended Sorry, her university is not listed and graduated in 2014 (around 10 years of experience). They are listed as doing telehealth appointments.

Emily L Hickson Office Phone and Directions

Emily Hickson
Mskcc Regional Network
650 Commack Rd
Commack, New York 11725
631-623-4034

Patient Ratings
Please rate your experience with Emily Hickson below to help others make a more informed decision. Thanks!

Current Rating: Loading...

Phone: 631-623-4034

Enter a starting address:

Healthcare Info for Emily Hickson

Medical School: Sorry, her university is not listed
Graduation Year: 2014
The Primary Medical Specialty for Emily Hickson is listed as: Nurse Practitioner
Approximate Years of Experience: 10
PAC (PECOS ID)#: 1759684657
NPI #: 1922402080
NPI Created On: 10/18/2014
NPI Last Updated Listed as: 10/14/2015
Primary Taxonomy Code: 363LA2200X
License Number:
F307116
Listed Gender: Female

Procedures, Services, Charges

Services and Procedures include:

Bone marrow biopsy
Established patient office or other outpatient, visit typically 40 minutes

Open Payments Data. This can include items to test (Durable Medical Equipment (DME)), Biological, Drug Samples, etc. This data must be reported to CMS.

Payments Total: $5

Number of Payments:: 1

Form of Payment: In-kind items and services

Ownership Interest:

Third party is a Charity:: No

Record ID:: 836027805

Being Disputed:: No

Product Related: Yes

Drug or Biological: Biological

Product Category #1: BioOncology

Name of Drug #1: POLIVY

Open Associated Drug #1: 50242-105-01